Entero Therapeutics, Inc.
ENTONASDAQHealthcare
$2.85
$-0.15(-5.00%)
Market Cap$13582331
P/E Ratio—
52W High$5.84
52W Low$0.969
Entero Therapeutics, Inc. (ENTO) · Cash Flow
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · ENTO · as of 2026-06-10
Financial statements
Operating CF · CapEx · Free Cash Flow
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | ($6.55M) | ($18.06M) | ($15.79M) | ($14.63M) | ($58.54M) |
| Depreciation & Amort. | $0.57M | $0.05M | $0.03M | $0.03M | $0.54M |
| Stock-Based Comp. | $0.73M | $0.63M | $1.04M | $0.77M | $1.37M |
| Change in Working Capital | $0.00M | $2.53M | $2.19M | ($10.50M) | $17.10M |
| Net Cash from Operations | ($5.70M) | ($9.22M) | ($12.38M) | ($22.34M) | ($32.29M) |
| Investing Activities | |||||
| Capital Expenditure | $0.00M | $0.00M | ($0.50M) | $0.00M | ($10.32M) |
| Purchases of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Sales of Investments | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Cash from Investing | $0.32M | $0.09M | ($0.50M) | $0.00M | ($10.32M) |
| Financing Activities | |||||
| Common Stock Repurchased | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Dividends Paid | ($0.34M) | $0.00M | $0.00M | $0.00M | $0.00M |
| Debt Issued / Repaid | $0.00M | ($0.64M) | ($0.60M) | ($0.64M) | $0.09M |
| Net Cash from Financing | $5.89M | $5.58M | $15.23M | $15.74M | $44.76M |
| Free Cash Flow | |||||
| Free Cash Flow | ($5.70M) | ($9.22M) | ($12.88M) | ($22.34M) | ($42.61M) |
| FCF Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-10 · USD · M
Explore more Entero Therapeutics, Inc. data
About Entero Therapeutics, Inc. (ENTO) Cash Flow Statement
Entero Therapeutics, Inc. generated operating cash flow of ($0.01B) and free cash flow of ($0.01B) for 2025 — a FCF margin of -15731.49%. Capital expenditure was $0.00B.
Frequently asked questions
ENTO · 4 questionsEntero Therapeutics, Inc. generated free cash flow of ($0.01B) for 2025, up 38.1% year-over-year.
ENTO free cash flowFCF margincash flow yield
· Source: FMP /stable/cash-flow-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-10